medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Blood biomarkers-defined subgroups show heterogeneity in post-acute COVID-19 syndrome: a rationale for precision medicine.

Benjamin Charvet[1], Alexandre Lucas[2], Justine Pierquin[1], Joanna Brunel[1], Steven Fried[3], Corinne Bernis[3], Zachary S. Orban[3], Millenia Jimenez[3], Barbara A. Hanson[3], Lavanya Visvabharathy[3], Igor J. Koralnik[3], Hervé Perron[1*], PhD.

[1]Geneuro-Innovation, Bioparc Laennec, 69008, Lyon, France.

[2.] We-Met platform, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-Met, Inserm UMR1297 and Université Paul Sabatier, Toulouse, France

[3] Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

*** Correspondence:** hperron@geneuro.com; Hervé Perron, Geneuro-Innovation, Bioparc Laënnec, 60A Avenue Rockefeller, 69008, Lyon, France. tel : +33 437 902 997

Keywords: long COVID-19, post-COVID-19, PASC, SARS-CoV-2, Immunoglobulin isotype, HERV-W, TLR4, cytokine, neurofilament, cognitive symptoms, brain fog.

Word count: 2741.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Acute COVID-19 can cause a post-infectious syndrome in a significant percentage of patients, with multifacted and long lasting symptoms. We hypothesized that this Post-Acute COVID syndrome (PASC) could result from various underlying causes, which may compromise the demonstration of efficacy for treatments evaluated on cohorts of heterogeneous patients.

To assess the feasibility of stratifying or characterizing subgroups of post-COVID-19 patients consistent with different indications in a precision medicine perspective, we tested serum biomarkers in a pilot cross-sectional study of patients with neuro-cognitive symptoms from the Northwestern University post-COVID-19 clinic (Chicago,USA). Patient health status was evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox. Serum biomarkers were chosen as proteins known to be involved in the pathogenic features of a neuro-inflammatory disease, i.e., multiple sclerosis, with a final selection of the most discriminant ones. A multi-isotypes serology against SARS-CoV-2 spike and nucleocapsid antigens was performed to allow detailed analyses of the humoral immune status.

Despite the limited numbers of this feasibility study, results showed that clinical data could not differentiate PASC patients with persisting neuro-cognitive impairment, while three major PASC subgroups were identified with serum biomarkers according to the presence or absence of the HERV-W ENV soluble protein combined with neurofilaments light chains and, to a lesser extent, with elevated levels of IL-6. SARS-CoV-2 serological results in PASC compared to healthy controls also revealed a significant increase of anti-Spike and/or Nucleocapsid IgM, IgA and, unexpectedly, IgE. For IgG, a significant difference was observed with Nucleocapsid only since anti-Spike IgG titers were normally elevated in vaccinated controls. This multi-Ig isotypes serology may provide additional information on the infectious and immunological status of individual patients and should be considered in face of a potential viral persistence in some individuals.

Altogether the results show the feasibility of using serum biomarkers to discriminate relevant subgroups or individual patients for precision medicine indications in post-COVID syndromes. This pilot study paves the way to further exploring biological assays for the definition of subtypes of PASC, also called long COVID, useful for the choice of relevant therapeutic strategies.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 Introduction

The COVID-19 pandemic is now known to generate a post-viral syndrome with multifaceted and long-lasting symptoms, variably named "Long COVID", "Post-COVID" or "Post-Acute sequelae of COVID-19 (PASC). Though the last denomination may suggest lingering post-infectious symptoms, e.g., ischemic tissue lesions following thrombotic events [1], many symptoms appear to result from ongoing pathogenic processes with possible onset of chronicity [2,3].

In June 2022, the center for disease control (CDC) of the USA published that "more than 40% of adults in the United States reported having COVID-19 in the past, and nearly one in five of those (19%) are currently still having symptoms of long COVID"[4]. In September 2022, the World Health Organization (WHO) published that "at least 17 million people in the WHO European Region experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come" [5]. The data points to a secondary pandemic caused by COVID-19, in the form of a post-COVID syndrome of unknown duration and evolution with overlapping symptoms that may result from various pathogenic factors and pathways [6]. In particular, persisting neurological and cognitive symptoms appear common and affect the quality of life on the long term [7,8].

Diagnosing and managing such a complex syndrome is a challenge that requires understanding how to identify potentially differing mechanisms underlying the overlapping symptoms observed in these patients [9]. There is a need to identify markers which will differentiate between heterogeneous long-COVID subgroups and guide precision medicine where possible. For this purpose, we have selected biomarkers from factors already known to be involved in COVID-19 and also suspected to contribute to certain aspects of long COVID or PACS. We also focused on assays suitable for routine laboratory analyses on serum samples, which can be easily obtained from patients.

In the present pilot study on patients from a post-COVID clinic presenting with persistent symptoms such as abnormal fatigue, sleep disorders and dominant neuro-cognitive symptoms, we have thus studied (i) immunoglobulin isotypes of the humoral response against SARS-CoV-2 spike and nucleocapsid antigens, (ii) the presence of an endogenous retroviral protein, HERV-W ENV, shown to be pathogenic for the immune and nervous systems [10-12], with virus-induced expression [13-15] and recently shown to predict disease severity when detected on lymphocytes from COVID-19 patients [16], (iii) the levels of major cytokines involved in COVID-19 inflammatory responses [17] and, because of neuro-cognitive symptoms, (iv) the levels of neurofilament light chain (NfL) known to be accurate biomarkers of neuronal impairment even when quantified in the peripheral blood [18].

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2 Methods

Participants and clinical assessment

This cross-sectional study was approved by the Northwestern University Institutional Review Board (STU00215866). Blood collection from patients and sample processing followed standard operating procedures with the appropriate approval of the Ethics and Scientific Committees (num. 20210604/04/02). Written informed consent was obtained from all study participants. Importation of the human samples received the authorization IE-2022-2309 from the French ministry. Clinical and demographic data from PASC patients are presented in **Table 1**. PASC patient health status was evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox [8,19,20].

Immunooassays

The detection of SARS-CoV-2 immunoglobulin isotypes (IgG, IgM, IgA and IgE) were performed on serum by Simple Western technology (ProteinSimple/BioTechne, CA, USA) with manufacturer's reagents according to their manual. HIS-tagged recombinant proteins of SARS-CoV-2 ((S)Spike, S1 Subunit, S2 Subunit, S1 RBD and Nucleocapsid were used to detect antibody responses to SARS-CoV-2. The area under the curve (AUC) for the electrophoregram peak corresponding to the immunodetection of each protein at the expected size was measured using Compass Software.

For the detection of HERV-W ENV antigen in serum analyses were also performed with simple western-Jess, according to the conditions provided in the patent "Method for the detection of the soluble hydrophilic oligomeric form of HERV-W envelope protein", published under ref. WO2019201908, with previously described sample treatment (32). The specific signal was expressed as the signal to noise (S/N) ratio, where the noise represents the mean+2SD of the background signals yielded by a panel of sera from healthy blood donors (EFS, Lyon-France). PASC samples were stored in freezers at -80ºC for less than 6 months. All samples were kept frozen after their initial freezing until use (no freeze/thaw cycle before the immunoassay).

Serum levels of NfL (# SPCKB-PS-002448) and IL-6 (# SPCKC-PS-006520) were quantified with the fully automated immunoassay platform, Ella (ProteinSimple/Bio-techne, CA, USA). The lower limits of quantification (LLOQ) were provided by the supplier as a threshold for normal baselines 3 pg/mL for IL-6. Age-standardized Z-scores were calculated for NfLs{Harp, 2022 #18599}. Serum samples were run in triplicate and results in pg/mL were calculated by the instrument software (SimplePlex Explorer, ProteinSimple/Bio-techne, USA).

RT-qPCR

Total RNA was obtained from PAXgene tubes used to collect whole blood samples and stored at -20°C. RNA extraction used NucleoSpin RNA Mini Kit (Macherey Nagel, 740955) according to the manufacturer's protocol. 200 ng of DNase-treated RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad, 1708891) according to the manufacturer's protocol. A control with no-RT was used to confirm the absence of contaminating DNA. 5 ng of initial RNA in RT reaction was used in RT-qPCR for HERV-W *ENV*, HERV-W *POL,* HERV-K *ENV,* SARS-CoV-2 N genes. Primer sequences (5' to 3'): HERV-K ENV Forward CTGAGGCAATTGCAGGAGTT, Reverse GCTGTCTCTTCGGAGCTGTT; HERV-W ENV Forward GTATGTCTGATGGGGGTGGAG, Reverse CTAGTCCTTTGTAGGGGCTAGAG; HERV-W POL Forward CCTGTACGTCCTGACTCTC, Reverse CTTGGGCTAATGCCTGGCC; SARS-CoV-2 N Forward AAACATTCCCACCAACAG,

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Reverse CACTGCTCATGGATTGTT; B2M Forward TTACTCACGTCATTCAGCAG, Reverse GATGGATGAAACCCAGACAC. Assays used StepOnePlus instrument (Applied Biosystems) with Platinum SYBR Green (Invitrogen, 11744-500). Housekeeping gene beta-2 microglobulin (*B2M*) normalized the results. A melting curve analysis confirmed the specificity of amplification and the lack of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the relative expression was calculated as follow: $2^{-[DCt\ (sample)\ -\ DCt\ (calibrator)]} = 2^{-DDCt}$, where DCt (sample) = [Ct (target gene) – Ct (housekeeping gene)] and the DCt (calibrator) was the mean of DCt of healthy controls.

Statistics

Statistical analyses were performed using Prism (version 9.0; GraphPad Software, La Jolla, California). Continuous data are expressed as means ± SD, as indicated. Normal data distribution was assessed using the Shapiro-Wilk or D'Agostino & Pearson's test, assuming p-values > 0.05. Statistical differences were determined using Student's test (two tailed) for compared groups with normal distributions, with Welch's correction when SDs of samples were significantly different (F test $p<0.01$) - Mann-Whitney U test (two tailed) was used for compared groups without normal distribution and Wilcoxon signed rank test (two tailed) was used for comparison when a group only or mostly comprised null or very low values for a given threshold. Chi-square (two tailed) test was used for comparison of numbers in categories, replaced by Fischer's exact test when one category had zero count. Correlation analyses were performed with Spearman test (two tailed). Statistical significance was set at $p<0.05$.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

3 Results

A total of 41 subjects (Table 1) were evaluated in this study. Controls (Ctrl) were caregivers or volunteers from hospital (n=10) and PASC patients previously diagnosed with acute COVID-19 and presenting with neuro-cognitive symptoms, (Neuro-PASC; n=31). These included 6 post-hospitalization Neuro-PASC (PNP) and 25 non-hospitalized Neuro-PASC (NNP) patients seen at Northwestern Medicine Neuro-COVID-19 clinic.

HERV-W ENV detection

Following reports of HERV-W envelope RNA and protein in acute COVID-19 patients correlating with disease severity and markers of T-cell exhaustion [16], this study analyzed HERV-W *ENV* RNA from whole blood and levels of soluble envelope protein (W-ENV) in serum from PASC compared to Ctrl. As shown in Figure 1 A-D, about one-half (11/23 with QC-passed RNA) of PASC individuals had elevated RNA levels and about one-third (10/31) had detectable W-ENV protein in serum, which was significantly different from Ctrl for both analyses (Wilcoxon Signed Rank test: Ctrl W=1.00, PASC W=177.00, N=7+23, p=0.0055 for whole blood RNA, and Ctrl W=10.00, PASC W=265.00, N=10+31, p=0.0020 for serum protein). RT-qPCR also detects non-coding RNA and it is known that HERV RNA could play physiological roles as regulatory non-coding long or small RNA [21,22]. Nevertheless, the presence of circulating W-ENV protein, a potent TLR4 agonist, cannot be neutral[12,23-26].

In Figure 1C PASC patients were stratified based on hospitalization status during acute SARS-CoV-2 infection. Positive cases for W-ENV protein represented about one fourth in the NNP subgroup (24%, 6/25), but a majority in the PNP subgroup (67%, 4/6). The difference of W-ENV signal to noise values (S/N) between NNP and controls was significant (Wilcoxon Signed Rank test: Ctrl W=1.00, PASC W=21.00, N=10+25, p=0.0313) but, probably due to the low numbers, not between PNP and Ctrl. Interestingly, W-ENV positive (W-ENV+) PASC patients tended to be further from the date of infection (Fig. 1D). A significant difference in the time from onset of acute COVID-19 between W-ENV+ and W-ENV- patients was confirmed (Unpaired t-test with Welch's correction: t=2,346, df=17,61, N=21+10, p=0.0309). Some of these cases had suffered from post-COVID symptoms for two years after the acute infection, which corresponded to the beginning of the pandemic.

SARS-CoV-2 -specific antibody responses

To study the humoral immune response to SARS-CoV-2 infection in PASC patients, we measured the levels of all immunoglobulins (IgG, IgM, IgA and IgE) versus the control group (including vaccinated individuals) against SARS-CoV-2 nucleocapsid (N) and spike (S) antigens.

Anti-N IgG were detected in a subgroup of PASC patients but not in controls (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC W=444.0, N=10+31, p<0.0001; Fig. 1E), whereas no difference with Ctrl was observed for the anti-S IgG (Fig. 1F), which mostly indicated that Ctrl had been vaccinated with this antigen. Comparing W-ENV positive and negative PASC patients showed that anti-N IgG antibodies were detected in both subgroups, each one remaining significantly different from Ctrl (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC/W-ENV- W=193.0, N=10+21, p=0.0003; Ctrl W=0.00, PASC/W-ENV+ W=53.0, N=10+10, p=0.0039; Fig. 1G), but no difference was seen between PASC subgroups and Ctrl for anti-spike IgG (Fig. 1H).

As shown in Figure 2, IgM against both S and N proteins were only observed in a subgroup of PASC patients with a wide range of titers. But, despite a few IgM positive PASC cases, a significant difference

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

was seen versus controls for anti-N IgM (Wilcoxon Signed Rank test: Ctrl W=1600, PASC W=476.0, N=10+31 p=0.0480; Fig. 2 A) and, with high significance, for anti-S IgM (Wilcoxon Signed Rank test: Ctrl W=-6.00, PASC W=183.0, N=10+29, p<0.0001; Fig. 2 B). Of note, two sera with non interpretable technical profiles were omitted.. IgA antibodies levels were shown to be significantly elevated in PASC versus Ctrl for both N and S antigens, but anti-N IgA better discriminated PASC versus Ctrl (Wilcoxon Signed Rank test: anti-N IgA, Ctrl W=16.00, PASC W=476.0, N=10+31 p<0.0001; anti-S IgA, Ctrl W=-2.00, PASC W=273.0, N=10+31 p=0.0063; Fig. 2 C-D). Surprisingly, a subgroup of PASC patients had elevated IgE immunoglobulins against both N and S antigens (Wilcoxon Signed Rank test: anti-N IgE, Ctrl W=5.00, PASC W=336.0, N=10+31 p=0.0006; anti-S IgE, Ctrl W=14.00, PASC W=456.0, N=10+31 p<0.0001), with a large range of positivity versus all negative controls (Fig. 2 E-F).

IL-6 quantification

IL-6 was suggested to play a role in acute COVID-19 severity. In PASC, only a subgroup had elevated IL-6 (about 35%, 11/31) but, whereas most values were below the normal threshold (3pg/ml) in NNP, nearly all PNP (5/6) had elevated IL-6 levels in the serum with a significant difference from Ctrl (Mann Whitney test: U=3, N=10+6, p=0.0017;Fig. 3A). When W-ENV positive and negative PASC subgroups were compared, the W-ENV+ patients showed significantly higher IL-6 levels (Mann Whitney test: U=31, N=21+10, p=0.0011; Fig. 3B), consistently with the significant correlation found between PASC serum levels of HERV-W ENV and IL-6 (Spearman correlation test: r=0.5877, 95% CI 0.2847 to 0.7840, pairs N=31, p=0.0005; Fig. 3C). In figure 3D, PASC were stratified according to both anti-N SARS-CoV-2 IgG and W-ENV serum levels. All samples from the W-ENV+ subgroup had elevated IL-6 levels, when compared to all other W-ENV negative sera with or without anti-N IgG (Mann Whitney test: W-ENV+/IgG N+ Vs W-ENV-/IgG N-, U=7, N=8+9, p=0.0035; W-ENV+/IgG N+ Vs W-ENV-/IgG N+, U=10, N=8+13, p=0.0013; Fig. 3D).

Neuronal impairment biomarker: Neurofilament Light chain (NfL)

We measured the levels of serum NfL in PASC with cognitive impairment, since shown to be an accurate peripheral biomarker of neuronal degeneration or injury within the central nervous system[27] (Figure 3E-G). Results were normalized with Z-score according to the age of the patients or control individuals, as already defined [28].

No significant difference was found between the distributions of NfL serum levels in PNP versus NNP, nor Vs Ctrl (Fig. 3 E). Nonetheless, when stratified with W-ENV, all (100%, 10/10) W-ENV+ patients had elevated levels of serum NfL while only 62% (13 out of 21) of W-ENV-negative sera had a NFL Z-scores above 0 (Fisher exact test = 0.0317 p<0.05, α=1, N=31; Fig. 3 F). Moreover, Z-scores were all above zero in the subgroup with both W-ENV and anti-N IgG positivity which was significantly different from the anti-N IgG+ and W-ENV- subgroup (Unpaired t test with Welch's correction: t=2,688, df=17,61, N=22, p= 0,0152; Fig. 3G),.

Biomarker-defined subgroups

Figure 3H represents clusters of all PASC patients studied for the above-mentioned serum biomarkers. Within the W-ENV+ subgroup the majority (7/10) of PASC were positive altogether for NfL, IL-6 and IgG anti N-SARS-CoV-2 but only one (1/21) in the W-ENV negative subgroup (Chi-square statistic=17.890, *p*=0.00002, α=1, N=31 tested on all parameters). All W-ENV+ Neuro-PASC had positive serum levels of NfL (10/10). Moreover, within the W-ENV + subgroup, the NfL+ cluster included all IL-6+ or Ig anti-N+ sera and therefore coincided with W-ENV positivity in Neuro-PASC patients, i.e., defined the same subgroup when combined with W-ENV positivity. Matching with acute COVID effective hospitalization also, all HERV-W ENV+ patients from the PNP subgroup were positive for the three other biomarkers (NfL, IL-6 and IgG anti-N; data not shown).

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Within the W-ENV- subgroup, a single case was positive for NfL, IL-6 and IgG anti-N altogether. As found to be the core parameters in the W-ENV+ subgroup, this may question the sensitivity of the present test for HERV-W ENV soluble antigen detection in serum. The patterns for single or double positivity appeared to be variable while only NfLs positive levels were dominant, thereby suggesting relationship with the neuro-cognitive impairment in this cohort. However, a cluster was clearly identified to be negative for all these biomarkers, beyond negativity for W-ENV as well. This "all negative" cluster is consistent with very different pathogenic factors involved in their post-COVID symptomatology.

Of note, though all W-ENV+ patients had positive Z-scores for NfL, taken alone this biomarker revealed dominant in all Neuro-PASC cases, W-ENV+ and W-ENV- (Figure 3F). Negative Z-scores were found in few cases positive for IL-6 only or for IgG anti-N only but, most interestingly, within the isolated cluster negative for all tested biomarkers (figure 3H).

SARS-CoV-2 serology showed significant differences with controls for anti-N IgG (Figure 1E) and for anti-N and/or anti-S IgM, IgA or IgE (Figures 2A-F). But, even in combination with other biomarkers, it did not provide a clear-cut stratification when considered without the other studied biomarkers.

Therefore, Neuro-PASC subgroups could be defined as (i) W-ENV+ and NfL+, (ii) W-ENV- and (NfL+ or IL-6+ or IgG anti-N+) and (iii) negative for all the tested parameters. In addition, possible indication may be also provided on SARS-CoV-2 persistence by IgM, on the route of infection in extrapulmonary cases[29] or on the site of persistence by IgA and, particularly, on potentially associated immunoallergic symptoms by IgE.

Finally, using data from the PROMIS scale[30] and other clinical data showed no significant difference in the distribution of results between the subgroups consistently defined by the different biomarkers as exemplified with HERV-W ENV and anti-N-SARS-CoV-2 IgG in Figure 4.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Conclusion

The present results, despite the limited number of patients, consistently identified three major Neuro-PASC subgroups with significant differences stratified according to the presence or absence of the HERV-W ENV protein combined with positive Z-score for NfLs in serum. SARS-CoV-2 serology with all Ig isotypes should also provide useful indications on the infectious status, with possible viral persistence or a possible immunoallergic specific phenotype linked to elevated anti-spike or Nucleocapsid IgE. Since clinical data could not differentiate consistent subgroups of patients, unlike biological parameters, the biomarker-defined subgroups or clusters may be considered for differing therapeutic indications in post-COVID treatment. This should be a prerequisite for clinical trials to avoid mixing patients with and without the pathogenic target of a given drug, which may generate non-significant results versus placebo, despite possibly responding cases. Thus, the presented biomarker and serology-based stratification should pave the way to precision medicine in post-acute COVID sequalae or syndromes. Based on the present proof of concept and on that of other studies , a diagnostic-based therapy with an anti-HERV-W ENV neutralizing antibody (Temelimab) is being evaluated in a clinical trial with PASC patients positive for the HERV-W ENV protein in serum (NCT).

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure Legends

Figure 1. **HERV-W ENV and Anti-Nucleocapsid IgG antibody are significantly detected in PASC.** A, HERV-W *ENV* mRNA detection in PBMCs based on change fold of $2^{-\Delta\Delta CT}$ compared to the mean of control groups; blue dots: controls group; red dots: PASC group. Here, a lower number of samples was analyzed, since 8 PASC and 3 controls yielded too low RNA concentration or did not pass QC (RIN<8). B, HERV-W ENV soluble oligomeric protein detection in serum of patients, results are expressed on total signal normalized with the mean of background noise measured on control cohort; blue dots : controls group; red dots : PASC group. C, post-hospitalized subgroup (PNP) is extracted from the PASC group and compared to PASC subgroup not hospitalized during acute COVID-19 (NNP); blue dots: controls group; red dots: NNP subgroup; dark red dots: PNP sub group. D, Comparison of the time from onset between HERV-W ENV- and HERV-W ENV+ PASC subgroups; grey dots: PASC HERV-W ENV- subgroup; orange dots: PASC HERV-W ENV+ subgroup. E, IgG anti-SARS-CoV-2 Nucleocapsid; F, IgG anti-SARS-CoV-2 Spike. Comparison between PASC HERV-W ENV- and PASC HERV-W ENV+ subgroups for IgG anti-Nucleocapsid (G), and anti-Spike (H). The value on the Y-axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig isotype from tested sera against each antigen.

Figure 2. **PASC serological IgM, IgA and IgE**. A, IgM anti-SARS-CoV-2 Nucleocapsid; B, IgM anti-SARS-CoV-2 Spike IgM anti-S and N of two PASC patients with inconsistent results and diverging triplicate values were not be interpretable and therefore not taken into account in this analysis.; C, IgA anti-SARS-CoV-2 Nucleocapsid; D, IgA anti-SARS-CoV-2 Spike; E, IgE anti-SARS-CoV-2 Nucleocapsid and F, IgE anti-SARS-CoV-2 Spike. The value on Y axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the immunodetected Ig isotype from tested sera against each antigen.

Figure 3. **Interleukine-6 (IL-6), neurofilament light chain (NfL) biomarkers and combination with HERV-W ENV or anti-nucleocapsid IgG (IgG anti-N) status stratifying PASC patients.** A, IL-6 dosages for controls (bleu dots), NNP (red dots) and PNP (dark red dots). B, IL-6 dosage comparisons between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. C, correlation between IL-6 and HERV-W ENV levels in serum. D, IL-6 levels in PASC patients stratified by: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-N+ (red dots). E, NfL Z-Scores of controls (blue dots), NNP (red dots) and PNP (dark red dots). NfL Z-scores comparisons between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. G, NfL levels in different PASC subgroups: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and HERV-W ENV+ / IgG anti-N+ (red dots). H, Graphical presentation of patients' clusters defined by the selected serum biomarkers, within HERV-W ENV negative and HERV-W ENV positive subgroups. The sera positive for each biomarker are represented by dots in the colored circles; those negative for all parameters are in the grey oval.

Figure 4. **Comparison of clinical data between groups based on HERV-W ENV and serology profiles.** Three groups from the PASC cohort are represented based on main biomarkers results: HERV-W ENV+ /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + ; HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + and HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N). Several parameters were studied: A, Processing speed; B, Attention; C, Executive function; D, Working Memory; E, Cognitive function; F, Fatigue; G, Anxiety; H, Depression and I, Recovery compared to the baseline.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Conflict of Interest

HP, BC, JB and BC receive compensation from Geneuro-Innovation for their work. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

IK : conceptualization of the study, evaluating all patients in the Neuro-COVID-19 clinic, supervising patients sample collection, manuscript editing and review

NW collaborators: Zack and Millenia: organized sample and data collection from all Neuro-PASC and control patients at Northwestern University, manuscript review

Barbara and Lavanya: Conceptualization of the study, assisted in sample and data collection from all Neuro-PASC and control patients at Northwestern University, editing and reviewing the manuscript

HP: conceptualization, supervision, formal analysis, investigation, data curation, writing and manuscript review.

AL, CB, SF: HERV-W-ENV detection, NfL, cytokines HERV-W-ENV detection, NfL, cytokines, serological analyses.

B.C.: methodology, management interpretation of analyses and manuscript review.

J.P: Serological and antigenemia analyses; graphs, figures drawing and manuscript review.

J.B.: PCR, serological and antigenemia analyses; graphs, figures drawing and manuscript review.

H.P. and E.O.: conceptualization, funding acquisition, supervision, formal analysis, investigation, data curation, writing original draft and manuscript review.

All authors contributed to the article and approved the submitted version.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Hamouda D, Jillella DV, Bhatt N, Koneru S, Frankel MR, Nogueira RG. Intraluminal carotid thrombosis and acute ischemic stroke associated with COVID-19. *J Neurol*. Dec 2021;268(12):4443-4447. doi:10.1007/s00415-021-10562-1

2. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. Nov 2020;7(11):2221-2230. doi:10.1002/acn3.51210

3. Nehme M, Braillard O, Chappuis F, CoviCare Study T, Guessous I. The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization. *Sci Rep*. Aug 25 2022;12(1):14505. doi:10.1038/s41598-022-18673-z

4. CDC. *Prevalence of long COVID in the USA*. 2022.

5. WHO. *Long COVID in the WHO European Region*. 2022.

6. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. Oct 25 2022;328(16):1604-1615. doi:10.1001/jama.2022.18931

7. Ali ST, Kang AK, Patel TR, et al. Evolution of neurologic symptoms in non-hospitalized COVID-19 "long haulers". *Ann Clin Transl Neurol*. Jul 2022;9(7):950-961. doi:10.1002/acn3.51570

8. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol*. May 2021;8(5):1073-1085. doi:10.1002/acn3.51350

9. O'Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and Challenges of the Clinical Diagnosis and Management of Long COVID. *JAMA Netw Open*. Nov 1 2022;5(11):e2240332. doi:10.1001/jamanetworkopen.2022.40332

10. Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. *J Immunol*. Jun 15 2006;176(12):7636-44.

11. Firouzi R, Rolland A, Michel M, et al. Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. *J Neurovirol*. Feb 2003;9(1):79-93. doi:10.1080/13550280390173328

MN2N2T34QVXHRWNY [pii]

12. Kremer D, Gruchot J, Weyers V, et al. pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. *Proc Natl Acad Sci U S A*. Jul 23 2019;116(30):15216-15225. doi:10.1073/pnas.1901283116

13. Ruprecht K, Obojes K, Wengel V, et al. Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. *J Neurovirol*. Feb 2006;12(1):65-71. doi:T6G5G8M106986441 [pii]

10.1080/13550280600614973

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

14. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-6A and CD46 Receptor Engagement. *Front Immunol*. 2018;9:2803. doi:10.3389/fimmu.2018.02803

15. Li F, Nellaker C, Sabunciyan S, et al. Transcriptional derepression of the ERVWE1 locus following influenza A virus infection. *J Virol*. Apr 2014;88(8):4328-37. doi:10.1128/JVI.03628-13

16. Balestrieri E, Minutolo A, Petrone V, et al. Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. *EBioMedicine*. Apr 2021;66:103341. doi:10.1016/j.ebiom.2021.103341

17. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. *Nat Immunol*. Feb 2022;23(2):165-176. doi:10.1038/s41590-021-01091-0

18. Fisse AL, Pitarokoili K, Leppert D, et al. Serum neurofilament light chain as outcome marker for intensive care unit patients. *J Neurol*. Apr 2021;268(4):1323-1329. doi:10.1007/s00415-020-10277-9

19. Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two sides of one coin? *Psychooncology*. Oct 2014;23(10):1133-41. doi:10.1002/pon.3522

20. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med Rehabil*. Oct 2011;92(10 Suppl):S20-7. doi:10.1016/j.apmr.2010.08.033

21. Wilson KD, Ameen M, Guo H, et al. Endogenous Retrovirus-Derived lncRNA BANCR Promotes Cardiomyocyte Migration in Humans and Non-human Primates. *Dev Cell*. Sep 28 2020;54(6):694-709 e9. doi:10.1016/j.devcel.2020.07.006

22. Chishima T, Iwakiri J, Hamada M. Identification of Transposable Elements Contributing to Tissue-Specific Expression of Long Non-Coding RNAs. *Genes (Basel)*. Jan 9 2018;9(1)doi:10.3390/genes9010023

23. Johansson EM, Bouchet D, Tamouza R, et al. Human endogenous retroviral protein triggers deficit in glutamate synapse maturation and behaviors associated with psychosis. *Science Advances*. 2020;6(29):eabc0708. doi:10.1126/sciadv.abc0708

24. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment. *J Neuroimmunol*. Feb 15 2016;291:29-38. doi:10.1016/j.jneuroim.2015.12.006

25. Duperray A, Barbe D, Raguenez G, et al. Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol*. Nov 2015;27(11):545-53. doi:10.1093/intimm/dxv025

26. Kremer D, Schichel T, Forster M, et al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. *Ann Neurol*. Nov 2013;74(5):721-32. doi:10.1002/ana.23970

27. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. *Ann Clin Transl Neurol*. Dec 2018;5(12):1478-1491. doi:10.1002/acn3.638

28. Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood neurofilament light chain. *Ann Clin Transl Neurol*. Apr 2022;9(4):444-453. doi:10.1002/acn3.51524

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

29. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. Jul 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3

30. Vartanian K, Fish D, Gronowski B, Kenton N, Robicsek A. Patient-Reported Outcomes for Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases. *Patient*. Nov 7 2022:1-12. doi:10.1007/s40271-022-00605-8

Figure 1

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 3

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 4

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



TABLE 1

medRxiv preprint doi: https://doi.org/10.1101/2023.03.31.23288003; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	Demographics		Clinical data												Neurological symptoms						Toolbox				PROMIS									
Group	Gender	Age	Days from 1rst vaccine	Days from 2nd vaccine	Days from 3rd vaccine	SARS-CoV-2 RT-PCR results	SARS-CoV-2 Antigen test	Days from acute onset	hospitalized for COVID-19?	Days hospitalized	pneumonia?	hypoxia?	intubated?	encephalopathy	Brain Fog	Fatigue	Anosmia	Dysgeusia	Depression / Anxiety	% recovered / baseline	Processing Speed T-score	Attention T-score	Executive Function T-score	Working Memory T-score	Cognitive Function T-score	Cognitive Function Category	Fatigue T-score	Fatigue Category	Anxiety T-Score	Anxiety Category	Depression T-Score	Depression Category	Sleep Disturbance T-Score	Sleep Disturbance Category
CT	Male	25-30	316	294	4	Negative			No		No	No								n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	55-60	355	334	58	Negative			No		No	No								n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	40-45	321	293		Negative			No		No	No								n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Female	40-45	344	323		Negative			No		No	No								n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	50-55	245	223		Negative														n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	60-65	283	50		Negative														n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	40-45	322	295	75	Negative														n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Female	40-45	309	281	53	Negative														n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
CT	Male	30-35	324	303	106	Negative														n.a	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
CT	Male	25-30	413	392	111	Negative														n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
PASC	Male	50-55	287	258		Positive	n.a	393	No		Yes	No			Yes	Yes	Yes	Yes	Yes	80	48	36	43	56	33	Moderate	57	Mild	64	Moderate	54	Normal	63	Moderate
PASC	Male	40-45	204	174		Positive	n.a	365	Yes	8	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	70	33	27	30	39	34	Moderate	71	Severe	59	Mild	54	Normal	77	Severe
PASC	Female	40-45	Unknown	Unknown	40	Positive	n.a	443	No		No	No			Yes	Yes	No	No	No	65	53	41	41	42	35	Moderate	57	Mild	54	Normal	48	Normal	56	Mild
PASC	Female	15-20	209	188		Positive	n.a	372	No		No	No			Yes	Yes	Yes	Yes	Yes	30	52	43	37	49	34	Moderate	69	Moderate	67	Moderate	56	Mild	62	Moderate
PASC	Female	25-30	235	214	26	Positive	n.a	605	No		No	No			Yes	Yes	No	No	Yes	25	50	48	66	63	36	Moderate	74	Severe	63	Moderate	62	Moderate	61	Moderate
PASC	Male	60-65	280	259		Positive	n.a	338	No		No	No			Yes	Yes	Yes	Yes	Yes	70	39	39	43	51	35	Moderate	66	Moderate	63	Moderate	52	Normal	62	Moderate
PASC	Female	45-50	115	94		Positive	n.a	541	No		No	No			Yes	Yes	No	No	Yes	50	35	36	37	54	29	Severe	74	Severe	75	Severe	60	Severe	60	Mild
PASC	Female	55-60	262	241		Positive	n.a	698	No		Yes	No			Yes	Yes	Yes	Yes	No	60	28	30	33	42	40	Mild	63	Moderate	57	Mild	47	Normal	60	Mild
PASC	Male	50-55				Positive	n.a	363	No		No	No			Yes	Yes	Yes	Yes	No	50	27	34	34	47	35,5	Moderate	62,7	Moderate	60,5	Moderate	51,2	Normal	64,1	Moderate
PASC	Male	35-40	235	214		Positive	n.a	638	No		No	No			Yes	Yes	Yes	Yes	Yes	95	63	51	65	42	46	Normal	51	Normal	64	Moderate	53	Normal	69	Moderate
PASC	Female	50-55	221	199		Positive	n.a	371	No		No	No			Yes	Yes	Yes	Yes	Yes	75	30	56	40	45	30	Moderate	76	Severe	69,5	Moderate	67,7	Moderate	62	Moderate
PASC	Female	50-55	252	231	32	Positive	n.a	616	Yes	5	No	Yes	No	No	Yes	Yes	Yes	Yes	Yes	60	26	37	28	39	32,1	Moderate	65,8	Moderate	73,8	Severe	67,3	Moderate	61,4	Moderate
PASC	Male	50-55	33	12		Positive	n.a	282	No		No	No			Yes	Yes	Yes	Yes	No	40	55	46	46	36	49	Normal	64	Moderate	58	Mild	42	Normal	61	Moderate
PASC	Female	35-40	242	207	23	Positive	n.a	377	No		No	No			Yes	Yes	No	No	No	70	39	30	33	50	30	Moderate	66	Moderate	49	Normal	43	Normal	53	Normal
PASC	Female	35-40	260			Positive	n.a	548	No		No	No			Yes	Yes	No	Yes	No	75	38	46	52	48	41	Mild	66	Moderate	65	Moderate	64	Moderate	69	Moderate
PASC	Female	60-65	243	222		Positive	n.a	360	No		No	No			Yes	Yes	Yes	Yes	Yes	50	56	37	44	60	32	Moderate	60	Mild	60	Mild	48	Normal	66	Moderate
PASC	Male	55-60	305	63		Positive	n.a	461	No		No	No			Yes	No	Yes	Yes	Yes	40	42	41	49	63	30	Moderate	64	Moderate	65	Moderate	57	Mild	61	Moderate
PASC	Female	25-30	340	319	97	n.a	n.a	316	No		No	No			Yes	Yes	No	No	Yes	70	72	48	52	48	33	Moderate	66	Moderate	60	Mild	55	Normal	53	Normal
PASC	Female	15-20	256	42		n.a	Positive	711	No		No	No			Yes	Yes	Yes	No	Yes	70	55	51	38	43	41,3	Mild	59,1	Mild	58	Mild	49,9	Normal	46,4	Normal
PASC	Male	25-30	274	243		Positive	n.a	444	No		No	No			Yes	Yes	No	No	No	80	53	51	67	45	35	Moderate	56	Mild	65	Moderate	58	Mild	53	Normal
PASC	Female	40-45	283	262	75	Positive	n.a	176	No		No	No			Yes	Yes	Yes	No	Yes	40	58	54	65	70	34	Moderate	76	Severe	56	Mild	58	Mild	62	Moderate
PASC	Male	30-35	148	127		n.a	Positive	44	No		No	No			Yes	Yes	No	No	No	90	61	49	47	50	40	Mild	57	Mild	58	Mild	57	Mild	56	Mild
PASC	Female	25-30	346	57		Positive	n.a	212	No		No	No			Yes	Yes	No	No	Yes	65	35	36	31	38	40	Mild	66	Moderate	63	Moderate	51	Normal	53	Normal
PASC	Female	55-60	358	336	44	Positive	n.a	138	No		No	No			Yes	Yes	Yes	Yes	No	60	47	46	69	46	38,1	Moderate	58	Mild	44	Normal	48	Normal	46,3	Normal
PASC	Female	40-45	410	189	88	Positive	n.a	486	No		No	No			Yes	Yes	Yes	Yes	Yes	90	69	62	76	51	40	Mild	62	Moderate	65	Moderate	64	Moderate	65	Moderate
PASC	Male	20-25	341	320		Positive	n.a	341	No		No	No			Yes	Yes	No	No	No	30	55	47	53	52	32	Moderate	74	Severe	64	Moderate	55	Normal	56	Mild
PASC	Female	55-60				Negative	n.a	524	No		No	No			Yes	Yes	Yes	Yes	No	60	45	60	81	46	47	Normal	57	Mild	45	Normal	46	Normal	46	Normal
PASC	Male	65-70	373			Positive	n.a	516	Yes	8	Yes	No	n.a	Unknown	Yes	Yes	Yes	Yes	No	25	41	64	53	60	50	Normal	57	Mild	46	Normal	42	Normal	56	Mild
PASC	Male	55-60	416	395	156	n.a	n.a	694	Yes	6	Yes	Yes	No	No	Yes	Yes	No	No	Yes	65	30	38	35	45	39,1	Moderate	64	Moderate	65,4	Moderate	57,6	Mild	58	Mild
PASC	Female	60-65	432	242		Positive	n.a	730	Yes	19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	85	33	33	45	55	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
PASC	Male	60-65	377	349	164	n.a	n.a	771	Yes	5	Yes	No	n.a	Yes	Yes	No	No	No	Yes	80	55	51	69	54	37	Moderate	65,9	Moderate	62,4	Moderate	65,6	Moderate	52	Normal